![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/en/news-release/2024/07/09/2910187/29446/en/ORLADEYO-berotralstat-Approved-in-Peru.html
https://www.globenewswire.com/news-release/2024/07/02/2907294/29446/en/BioCryst-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://pharmaphorum.com/news/kalvista-files-first-oral-demand-hae-drug-fda
https://www.globenewswire.com/news-release/2024/06/04/2892929/29446/en/BioCryst-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/14/2881234/29446/en/BioCryst-to-Present-New-Data-at-2024-Meeting-of-the-European-Academy-of-Allergy-and-Clinical-Immunology.html
https://www.globenewswire.com/news-release/2024/05/09/2878592/29446/en/BioCryst-Presents-New-Real-world-Evidence-Showing-Significant-Reductions-in-Healthcare-Resource-Utilization-Among-Patients-with-HAE-Following-Initiation-of-ORLADEYO-berotralstat.html
https://www.globenewswire.com/news-release/2024/05/07/2876524/29446/en/BioCryst-to-Present-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com/news-release/2024/05/06/2875683/29446/en/BioCryst-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/05/03/2875025/29446/en/BioCryst-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/04/22/2866737/29446/en/BioCryst-to-Report-First-Quarter-2024-Financial-Results-on-May-6.html